lenalidomide has been researched along with Prostatic Neoplasms, Castration-Resistant in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barata, PC; Cooney, M; Dreicer, R; Garcia, JA; Mendiratta, P; Tyler, A | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Triozzi, P; Tyler, A | 1 |
| Kelby, SK; Lestingi, TM; Nabhan, C; Patel, A; Tolzien, K; Villines, D | 1 |
| Britton, HC; Loberiza, FR; McGuire, TR; Meza, JL; Schwarz, JK; Talmadge, JE; Wang, J | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Olza, MO; de Wit, R; Doner, K; Fandi, A; Fizazi, K; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, S; Petrylak, DP; Sternberg, CN; Van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
| Song, DK; Xing, DL; Zhang, LR | 1 |
| Adesunloye, BA; Arlen, PM; Beedie, SL; Chen, C; Chun, G; Cordes, L; Couvillon, A; Dahut, WL; Dawson, NA; Figg, WD; Gulley, JL; Harold, N; Huang, X; Karzai, FH; Lee, MJ; Lee, S; Madan, RA; McLeod, DG; Ning, YM; Rosner, I; Sissung, T; Steinberg, SM; Theoret, MR; Tomita, Y; Trepel, JB | 1 |
| Barton, D; Bellmunt, J; Berry, WR; Burke, JM; Crane, E; De Wit, R; Doner, K; Fandi, A; Fizazi, K; Gandhi, A; Hainsworth, JD; Hutson, TE; Jungnelius, U; Liu, K; Petrylak, DP; Sternberg, CN; Vogelzang, NJ; Waldman, MF; Wiechno, PJ | 1 |
| Barton, D; Bellmunt, J; Budnik, N; Burke, JM; Choudhury, A; de Morrée, ES; de Wit, R; Doner, K; Fandi, A; Flechon, A; Gschwend, JE; Houede, N; Jungnelius, U; Kopyltsov, E; Li, JS; Li, S; Ochoa de Olza, M; Petrylak, DP; Sternberg, CN; van As, N; Vogelzang, NJ; Wiechno, PJ | 1 |
8 trial(s) available for lenalidomide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Ketoconazole plus Lenalidomide in patients with Castration-Resistant Prostate Cancer (CRPC): results of an open-label phase II study.
Topics: Aged; Aged, 80 and over; Humans; Ketoconazole; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Time-to-Treatment; Treatment Outcome | 2018 |
Sargramostim (GM-CSF) and lenalidomide in castration-resistant prostate cancer (CRPC): results from a phase I-II clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Dendritic Cells; Drug Administration Schedule; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunologic Factors; Immunotherapy; Lenalidomide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Recombinant Proteins; Survival Analysis; T-Lymphocytes, Regulatory; Thalidomide; Time Factors; Treatment Outcome | 2014 |
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression; Disease-Free Survival; Humans; Lenalidomide; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Surveys and Questionnaires; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cyclophosphamide; Cytokines; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lenalidomide; Leukocytes; Male; Maximum Tolerated Dose; Middle Aged; Myeloid Cells; Neoplastic Cells, Circulating; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Thalidomide; Time Factors; Treatment Outcome | 2015 |
Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Placebos; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2015 |
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Bevacizumab; Humans; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Thalidomide | 2016 |
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lenalidomide; Male; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Taxoids; Thalidomide | 2017 |
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids; Thalidomide | 2017 |
1 other study(ies) available for lenalidomide and Prostatic Neoplasms, Castration-Resistant
| Article | Year |
|---|---|
Lenalidomide in treating patients with castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Follow-Up Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Lenalidomide; Male; Meta-Analysis as Topic; Neoplasm Staging; Prognosis; Prostatic Neoplasms, Castration-Resistant; Thalidomide | 2015 |